Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.
CLYM · Climb Bio, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Climb Bio is advancing BUDO toward a phase three PMN study and its APRIL antibody toward phase three IgA nephropathy development, with cash runway into the second half of 2028.
Climb Bio, Inc. launched an automatic shelf registration allowing future sales of multiple securities, with offering amounts and terms to be determined.
Budoprutug produced deeper peripheral B-cell depletion at 600 mg, with mean suppression of 98% at Week 4. Climb Bio, Inc. reported $227.6 million in cash and marketable securities on September 30, 2026, funding operations into the second half of 2028.
Climb Bio began dosing in the NAVIGATE-2 Phase 2 trial for IgAN. Budoprutug’s 200 mg cohort demonstrated B-cell depletion, PLA2R antibody reductions, and immunologic remission at Week 12.
Climb Bio reported initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy, with a mean PLA2R antibody reduction of 70% at Week 12 in the 200 mg cohort. The 600 mg cohort showed mean peripheral CD20+ B-cell suppression of 98% at Week 4, versus 74% at 200 mg. The drug was generally well tolerated, and additional Phase 2 data are anticipated in 2027.
Climb Bio and Mabworks reported additional Phase 1 CLYM116/MIL116 data in healthy volunteers. CLYM116 showed an estimated half-life of approximately 33 days, and a single SC injection of 480 mg or higher produced free APRIL suppression of 90% or more through the full 12-week dosing interval. An 800 mg dose produced approximately 70% reduction in Gd-IgA1 at 12 weeks.